Naomi Watts on HRT and Menopause: Press Coverage, Public Statements, and What the Science Says

Why Naomi Watts Became a Menopause Advocate

Watts has traced her advocacy back to a single clinical experience: being told in her mid-30s that her fertility window was closing, with little explanation of what perimenopause would mean for her body or brain. In a 2023 interview with The Cut, she described the encounter as isolating, noting that no physician at the time connected her anxiety, insomnia, and irregular cycles to hormonal shifts.

The Personal Timeline

She has stated publicly that symptoms began around age 36. Premature ovarian insufficiency (POI), defined as loss of ovarian function before age 40, affects approximately 1% of women according to a 2016 review in Human Reproduction Update 1. POI carries long-term risks for bone density, cardiovascular health, and cognitive function, which makes early identification and treatment a clinical priority.

From Silence to Public Disclosure

For years, Watts kept her experience private. She has said the turning point came during conversations with friends who were going through similar symptoms in their 40s and had no framework for understanding them. By 2022, she launched Stripes and began giving interviews that named specific symptoms: brain fog, joint pain, sleep disruption, and mood changes. "I felt like I was losing my mind, and nobody was telling me why," she told InStyle in late 2022.

That statement aligns with survey data. A 2021 study published in Menopause found that 73% of women with menopausal symptoms did not receive treatment, and 44% said they had never discussed menopause with a healthcare provider 2.

What Watts Has Said About Hormone Replacement Therapy

Watts has been careful in her public language around HRT. She has not disclosed a specific prescription regimen. In podcast appearances and print interviews, she has consistently framed her message around access to information rather than endorsement of a particular drug.

Key Public Statements

In a 2023 episode of the Dear Media podcast, Watts said: "I'm not here to tell anyone what to take. I'm here to say you deserve a conversation with your doctor where menopause is actually discussed." She repeated a similar point at the 2023 Galvanize summit, where she appeared alongside gynecologists and endocrinologists.

In her 2024 memoir Dare I Say It, Watts wrote about consulting multiple physicians before finding one who took her symptoms seriously. She described being offered antidepressants before anyone measured her hormone levels. This experience mirrors a pattern documented in a 2019 survey from The Menopause Society (formerly NAMS), which found that only 20% of OB-GYN residency programs provided any menopause training 3.

Inference Disclosure

Watts has not confirmed publicly whether she currently uses systemic estrogen, progesterone, or any other prescription HRT formulation. Any claim that she "takes HRT" is inference based on her advocacy, not a confirmed statement. HealthRX treats unconfirmed protocol details as speculative until verified by a primary source.

The Clinical Evidence Behind Early Menopause and HRT

The medical case for HRT in women with premature menopause is stronger than for menopause occurring at the typical age of 51. Guidelines from multiple professional societies recommend hormone therapy for women with POI unless a clear contraindication exists.

Cardiovascular and Bone Protection

The Endocrine Society's 2015 clinical practice guideline on POI recommends systemic estrogen therapy, combined with a progestogen for women with a uterus, continued at minimum until the average age of natural menopause (approximately 51) 4. The rationale is straightforward: women who lose estrogen early face accelerated bone loss and increased cardiovascular mortality if left untreated.

A 2019 meta-analysis in JAMA Internal Medicine found that women with premature menopause who did not receive HRT had a 50% higher risk of coronary heart disease compared to women who reached menopause at the normal age 5.

The WHI in Context

Much of the public fear around HRT traces to the Women's Health Initiative (WHI), first reported in 2002. The initial results showed increased breast cancer and cardiovascular events in the estrogen-plus-progestin arm. But the WHI enrolled women with a mean age of 63, well past the menopause transition.

The 2007 WHI reanalysis, published in JAMA, stratified results by age and found that women aged 50 to 59 who received estrogen alone had a non-significant trend toward reduced coronary events and a statistically significant reduction in all-cause mortality during the intervention phase 6. The timing hypothesis, now supported by over a decade of subsequent data, holds that HRT initiated within 10 years of menopause onset carries a different risk profile than HRT started decades later.

Current Guideline Consensus

The 2022 Menopause Society position statement affirms that for symptomatic women under age 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks 7. This applies even more directly to women with POI, for whom HRT is considered replacement of a physiologic deficit, not supplementation.

Stripes: What the Brand Does and Does Not Offer

Watts founded Stripes in 2022 as a direct-to-consumer brand focused on menopause. The product line includes topical skincare (body creams, vaginal moisturizers), supplements, and educational content. Stripes does not sell prescription hormones.

Product Positioning

The brand's marketing centers on normalizing menopause rather than medicalizing it. Products target common complaints like vaginal dryness, skin changes, and sleep quality. The vaginal moisturizer contains hyaluronic acid, not estradiol. The supplements include ingredients like ashwagandha, black cohosh, and magnesium.

This is a relevant distinction. A 2012 Cochrane review found insufficient evidence to support black cohosh for menopausal vasomotor symptoms, with most trials being small and methodologically limited 8. Ashwagandha has shown some promise for stress and sleep in small trials, but it is not FDA-approved for any menopausal indication.

Where Advocacy and Commerce Overlap

Watts has acknowledged this tension in interviews. She told Allure in 2023 that Stripes was "never meant to replace what your doctor should be doing" and described the brand as a "bridge" for women who feel ignored by the medical system. The distinction matters clinically: topical moisturizers and OTC supplements address symptoms differently than systemic estrogen, and they do not confer the cardiovascular or skeletal protection that prescription HRT provides for women with POI.

How Watts' Advocacy Compares to the Medical Literature

Watts' core public message, that menopause is under-discussed, under-diagnosed, and under-treated, is well supported by data. Where her advocacy stays clinical, it aligns with the evidence. Where it blurs into product marketing, patients should understand the difference.

What She Gets Right

The claim that physicians often fail to identify perimenopause is documented. A 2023 UK study published in BMJ Open found that women waited an average of 14 months between first reporting symptoms and receiving a menopause-related diagnosis, with many initially prescribed antidepressants or anxiolytics 9. Watts' description of her own diagnostic delay maps onto this pattern.

Her emphasis on starting the conversation early has clinical support. The American College of Obstetricians and Gynecologists (ACOG) recommends that clinicians counsel women about menopause proactively, beginning in the perimenopausal years, and discuss the full range of treatment options including hormonal and non-hormonal therapies 10.

What Requires More Nuance

Watts' public statements do not typically distinguish between systemic HRT (oral or transdermal estradiol with progesterone) and localized treatments (vaginal estrogen, OTC moisturizers). For a general audience, this can create confusion. Vaginal estrogen treats genitourinary syndrome of menopause (GSM) but does not address systemic symptoms like vasomotor flushes or bone loss. Systemic HRT does both but carries a different risk-benefit profile, particularly regarding breast cancer with long-term combined estrogen-progestogen use.

The 2020 Lancet meta-analysis of worldwide epidemiological evidence on HRT and breast cancer found that current users of combined HRT for 5 or more years had a relative risk of 1.60 for breast cancer 11. For estrogen-only therapy, the risk increase was smaller. These numbers require individualized assessment, and they are why the Menopause Society recommends the lowest effective dose for the shortest appropriate duration.

The Broader Celebrity Menopause Conversation

Watts is one of several public figures who have brought menopause into mainstream media. Her approach differs from some peers in that she has consistently deferred to medical professionals and avoided making specific drug claims.

A Comparison of Messaging Styles

Other celebrities have taken more prescriptive positions. Some have endorsed specific compounding pharmacies or named bioidentical formulations. Watts has not. Her messaging has stayed closer to the framework advocated by ACOG and The Menopause Society: encouraging patients to seek qualified medical advice and to view menopause as a health event that warrants clinical attention.

Media Impact

Since Watts began speaking publicly about menopause in 2022, media coverage of HRT and perimenopause has increased measurably. A 2023 analysis in The Guardian documented a 300% increase in UK Google searches for "perimenopause symptoms" between 2019 and 2023, driven partly by celebrity disclosure. While attribution to any single public figure is impossible, Watts' visibility, combined with her founding of a consumer brand, has placed her at the center of the conversation.

The risk, as with all celebrity health advocacy, is that consumer-facing products can be conflated with evidence-based medical treatment. A Stripes vaginal moisturizer is not vaginal estrogen. A supplement containing black cohosh is not transdermal estradiol. Watts has been more disciplined than many in maintaining this distinction, but patients should verify any treatment with a board-certified provider.

What Women with Early Menopause Should Actually Do

For women experiencing premature menopause or early perimenopause, as Watts has described in her own case, the clinical pathway is well defined.

Step One: Get Tested

Follicle-stimulating hormone (FSH) and estradiol levels, measured in the early follicular phase, can help confirm menopausal status. Anti-Müllerian hormone (AMH) offers additional information about ovarian reserve. The Endocrine Society recommends repeat testing to confirm POI, as a single elevated FSH level can occur in women with intact ovarian function 4.

Step Two: Discuss HRT With a Menopause-Trained Clinician

Not all OB-GYNs have menopause training. The Menopause Society maintains a provider directory of certified menopause practitioners. For women with confirmed POI, systemic estrogen therapy (plus a progestogen if the uterus is present) is standard of care, continued until at least age 50 to 51.

Step Three: Monitor and Reassess

HRT is not a set-and-forget prescription. The Endocrine Society recommends annual reassessment of symptoms, bone density monitoring with dual-energy X-ray absorptiometry (DEXA) at baseline and at intervals determined by risk factors, and cardiovascular risk evaluation 4.

Women with POI who receive appropriate HRT have been shown to maintain bone mineral density comparable to premenopausal women, according to a 2017 study in Osteoporosis International 12.